A radioimmunoassay for danazol (17alpha-pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol).
A method is described for the radioimmunoassay of circulating levels of the pituitary inhibiting agent, danazol. An antigen for danazol was prepared by reacting a 17-carboxy-methyloxime derivative of danazol with bovine serum albumin. By immunizing rabbits with this antigen, antiserum was generated which shows excellent specificity for danazol relative to its known metabolites as well as to many natural steroids. A radioimmunoassay was developed, without using separation or extraction techniques, involving competition for the antiserum between danazol in plasma and 14C-danazol. This assay has been successfully used to measure danazol in a series of normal human subjects receiving the drug at either 100 or 200 mg b.i.d. for 2 weeks. A significant relationship was seen between dosage of danazol and plasma concentrations.
D000818:Animals; D000918:Antibody Specificity; D003613:Danazol / Q000032:analysis* / Q000097:blood; D005260:Female; D006241:Haptens; D006801:Humans; D011245:Pregnadienes / Q000032:analysis*; D011817:Rabbits; D011863:Radioimmunoassay / Q000379:methods
D006241:Haptens; D011245:Pregnadienes; D003613:Danazol